From L-R: Rondo CEO Shelley Force Aldred and CSO Nathan Trinklein

A dy­nam­ic on­col­o­gy duo team up on an I/O start­up fo­cused on next-gen sol­id tu­mor fight­ers

In the no­to­ri­ous­ly flighty biotech in­dus­try, long­time part­ner­ships aren’t nec­es­sar­i­ly the norm. But a pair of on­col­o­gy vets with a his­to­ry of col­lab­o­ra­tion ap­par­ent­ly likes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.